Clinical evaluation of haloprogin.
作者信息
Hermann H W
出版信息
Toxicol Appl Pharmacol. 1972 Dec;23(4):598-605. doi: 10.1016/0041-008x(72)90100-7.
PMID:4264777
Abstract
摘要
相似文献
1
Clinical evaluation of haloprogin.
Toxicol Appl Pharmacol. 1972 Dec;23(4):598-605. doi: 10.1016/0041-008x(72)90100-7.
2
Clinical efficacy studies of haloprogin, a new topical antimicrobial agent.新型外用抗菌剂卤普罗近的临床疗效研究
Arch Dermatol. 1972 Dec;106(6):839-42.
3
Haloprogin therapy for dermatophyte infections.
Arch Dermatol. 1972 Dec;106(6):837-8.
4
A controlled study of haloprogin and tolnaftate in tinea pedis.
Curr Ther Res Clin Exp. 1972 Jun;14(6):307-10.
5
Haloprogin for tinea.
Med Lett Drugs Ther. 1973 Aug 17;15(17):69-70.
6
Tolnaftate, a potent topical antifungal agent.
Arch Dermatol. 1965 Apr;91(4):372-6. doi: 10.1001/archderm.91.4.372.
7
The use of itraconazole to treat cutaneous fungal infections in children.伊曲康唑用于治疗儿童皮肤真菌感染。
Dermatology. 1999;199(3):248-52. doi: 10.1159/000018256.
8
Antifungal activity of the new agent latoconazole in two tinea models.
Arzneimittelforschung. 1991 Aug;41(8):847-51.
9
A comparison of the efficacy of oral fluconazole, 150 mg/week versus 50 mg/day, in the treatment of tinea corporis, tinea cruris, tinea pedis, and cutaneous candidosis.
Int J Dermatol. 1998 Sep;37(9):703-5. doi: 10.1046/j.1365-4362.1998.00541.x.
10
Tolnaftate in the treatment of superficial mycotic infections.
Southeast Asian J Trop Med Public Health. 1972 Jun;3(2):277-9.
Zotero 插件